Update on ARI-0001 for patients with CD19+ R/R malignancies

Marta Palhas — Fri, 26 Feb 2021 14:08:23 +0000

ARI-0001 is a novel second-generation autologous CD19 CAR-T cell that was evaluated in the Phase I CART19-BE-01 trial (NCT03144583). Clinical data showed ARI-0001 to be a safe and efficacious product, with persistence of CAR T-cells and response in patients with CD19+ relapsed/refractory (R/R) hematological malignancies. The CAR-T product is currently under review for approval by the Spanish Drug Agency (AEMPS) under the Hospital Exemption Rule. Manel Juan Otero, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses the next steps for ARI-0001, including in combination with other approaches and finding new indications for the CAR-T product such as in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. Additionally, Dr Juan Otero reveals that a new CAR T-cell targeting BCMA is being evaluated in multiple myeloma. This interview took place during the 3rd European CAR T-cell Meeting.

CART19-BE-01: ARI-0001 in CD19+ malignancies

admin_vjr_user — Tue, 03 Nov 2020 17:40:00 +0000

Valentín Ortiz-Maldonado, MD, of the Hospital Clinic, Barcelona, Spain, discusses the initial results of the CART19-BE-01 (NCT03144583), a Phase I multicenter study evaluating ARI-0001, a CD19 targeting chimeric antigen receptor T-cell, in patients with CD19+ relapsed/refractory hematological malignancies. The primary and secondary endpoints of safety and efficacy were met, with an overall survival of 68.6% at one year. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

CART19-BE-01 – VJRegenMed

Update on ARI-0001 for patients with CD19+ R/R malignancies

CART19-BE-01: ARI-0001 in CD19+ malignancies